These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25433360)

  • 61. Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.
    Narayan R; Galligan D; Lazar AA; Kim S; Fong R; Tan M; Lo M; Arora S; Shah N; Wong SW; Martin T; Wolf J
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e961-e985. PubMed ID: 32839138
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
    Bockorny M; Chakravarty S; Schulman P; Bockorny B; Bona R
    Acta Haematol; 2012; 128(4):244-7. PubMed ID: 22964848
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
    Gavazzoni M; Vizzardi E; Gorga E; Bonadei I; Rossi L; Belotti A; Rossi G; Ribolla R; Metra M; Raddino R
    Eur J Pharmacol; 2018 Jun; 828():80-88. PubMed ID: 29550338
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Carfilzomib-induced thrombotic microangiopathy. A case report.
    Scheggi V; Merilli I; Cesaroni E; Alterini B
    J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
    Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
    J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
    Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gastrointestinal toxicities of proteasome inhibitor therapy.
    Shah J; Devalaraju S; Baerman E; Lee IJ; Takigawa K; Machado AP; Catinis C; Shatila M; Varatharajalu K; Shafi M; Lee HC; Strati P; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):334. PubMed ID: 38969842
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
    Lonial S; Boise LH
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():25-31. PubMed ID: 25188480
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
    Zangari M; Aujay M; Zhan F; Hetherington KL; Berno T; Vij R; Jagannath S; Siegel D; Keith Stewart A; Wang L; Orlowski RZ; Belch A; Jakubowiak A; Somlo G; Trudel S; Bahlis N; Lonial S; Singhal S; Kukreti V; Tricot G
    Eur J Haematol; 2011 Jun; 86(6):484-7. PubMed ID: 21477075
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Proteasome inhibitor-induced gastrointestinal toxicity.
    Stansborough RL; Gibson RJ
    Curr Opin Support Palliat Care; 2017 Jun; 11(2):133-137. PubMed ID: 28333868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multidirectional pattern of hair growth with carflizomib use for multiple myeloma.
    Tuler S; Kaur J; Delaware S; Dasanu CA
    J Oncol Pharm Pract; 2021 Jul; 27(5):1291-1295. PubMed ID: 33050803
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
    Rosenthal A; Luthi J; Belohlavek M; Kortüm KM; Mookadam F; Mayo A; Fonseca R; Bergsagel PL; Reeder CB; Mikhael JR; Stewart AK
    Blood Cancer J; 2016 Jan; 6(1):e384. PubMed ID: 26771810
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
    Usmani SZ; Lonial S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies:
    Georgiopoulos G; Makris N; Laina A; Theodorakakou F; Briasoulis A; Trougakos IP; Dimopoulos MA; Kastritis E; Stamatelopoulos K
    JACC CardioOncol; 2023 Feb; 5(1):1-21. PubMed ID: 36875897
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
    Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative mechanisms of action of proteasome inhibitors.
    Wang M
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.